GlassScriptPhysician profile
Michael Anthony Tilson
NPI 1801242334
$3,031.82
in general payments reported to CMS, 2019-2025
24 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $206 · 2023: $126 · 2024: $1,074 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,312.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $615.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $442.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $404.91 | 2019-2025 | |
| Abbvie INC. | $286.76 | 2019-2025 | |
| Amgen INC. | $261.51 | 2020-2025 | Evenity, Otezla, Repatha |
| Exact Sciences Corporation | $157.71 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $111.09 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $105.31 | 2024-2025 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.94 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $75.18 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $72.95 | 2019-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $62.38 | 2019-2020 | |
| Antares Pharma, INC. | $61.52 | 2024-2025 | Xyosted |
| Sumitomo Pharma America, INC. | $45.09 | 2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.23 | 2025 | Caplyta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $32.32 | 2024-2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $32.21 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.16 | 2019-2024 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $22.13 | 2025 | Keveyis |
| Mylan Pharmaceuticals INC. | $20.95 | 2019 | |
| Bioventus LLC | $20.38 | 2025 | Supartz Fx Sodium Hyaluronate |
| Azurity Pharmaceuticals, INC. | $20.38 | 2024 | Edarbi |
| Genentech USA, INC. | $17.61 | 2019 | |
| Viatris Specialty LLC | $16.91 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.